Expression of Fas in renal cell carcinoma

Japanese Journal of Clinical Oncology
S HorieK Kawabe

Abstract

We have investigated whether the Fas-mediated cell death pathway is functional in renal cell carcinoma. The expression of Fas in surgical specimens and cell lines of renal cell carcinoma was examined. Fas expression was positive in six out of 18 tumors measured by flow cytometry and was prominent in advanced tumors. Three out of the six Fas-positive tumors had already metastasized at the time of surgery. A significant correlation was found between the tumor volume and the percentage of Fas-positive cells in a tumor (r = 0.70, P = 0.0007). Fas-positive tumors were larger than Fas-negative tumors [mean tumor volume (ml) +/- SD, Fas(+), 265.6 +/- 136.8; Fas(-), 65.8 +/- 80.9, P = 0.0012]. All human renal carcinoma cell lines tested (ACHN, Caki-1, SMKT-R-2, SMKT-R-3 and SMKT-R-4) expressed Fas abundantly, as Fas-positive cells accounted for > 50% in all cell lines by flow cytometry. Treatment with anti-Fas antibody caused apoptosis in Fas-positive renal cell carcinoma cell lines. However, the effectiveness of apoptosis induction in individual cell lines was not correlated with the level of Fas expressed. These data suggest that Fas targeting may be a therapeutic option for treatment of advanced renal cell carcinoma which is refract...Continue Reading

References

Jan 1, 1992·Urologia Internationalis·T TsukamotoM Satoh
Dec 1, 1992·The Journal of Urology·T TsukamotoM Yanase
Jan 1, 1985·Virchows Archiv. A, Pathological Anatomy and Histopathology·N MoriyamaT Niijima
Mar 10, 1995·Science·S Nagata, P Golstein
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P LipponenK Syrjänen
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S VesalainenK Syrjänen
Aug 1, 1994·The Journal of Pathology·P K Lipponen, S Aaltomaa
Apr 15, 1994·Cancer·J F KerrB V Harmon

❮ Previous
Next ❯

Citations

Mar 14, 2000·Annals of Surgery·M KornmannM Korc
Dec 7, 2000·Cancer Investigation·N DoninJ Leibovici
Apr 29, 2006·International Journal of Urology : Official Journal of the Japanese Urological Association·Takehiro Sejima, Ikuo Miyagawa
Jun 6, 2000·Biochimica Et Biophysica Acta·S KayJ Leibovici
Mar 9, 2012·Urologia Internationalis·Takehiro SejimaAtsushi Takenaka
Feb 18, 1999·The Journal of Urology·S HorieT Kitamura
May 18, 2019·Cell Death & Disease·Tobias LuebkeIngo Schmitz
Mar 4, 2003·Human Pathology·Uwe RampClaus Dieter Gerharz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis